

BOOM & DOOM

PROTECTING & BUILDING YOUR FINANCIAL FUTURE



INVESTOR'S DAILY EDGE



MT. VERNON
RESEARCH

Profit from the Next 1,000% Rally in Biotech

Marc Lichtenfeld

June 7, 2009

BOOM & DOOM

PROTECTING & BUILDING YOUR FINANCIAL FUTURE



INVESTOR'S DAILY EDGE



MT. VERNON
RESEARCH

10,000% Return in 10 years



BOOM & DOOM

PROTECTING & BUILDING YOUR FINANCIAL FUTURE



INVESTOR'S DAILY EDGE



MT. VERNON
RESEARCH

10,000% Return in 5 years



BOOM & DOOM

PROTECTING & BUILDING YOUR FINANCIAL FUTURE



INVESTOR'S DAILY EDGE



MT. VERNON
RESEARCH

\$10K into \$2.4 million





F.I.R.S.T. System

- Financials
- Interviews
- Research
- Safety
- Timing

Clinical Trials

Phase I -- <100 healthy volunteers, study pharmacokinetics.

Phase II -- Few dozen to few hundred patients. Study safety and efficacy in diseased patients

Phase III -- Few hundred to few thousand patients. Study safety and efficacy

Attributes to look for

- Market to themselves
- Unknown or unloved
- Game changing technology -- Wow! Factor

Institutional Investors You Should Know

- Baker Brothers Advisors -- (New Holdings - AMGN, CPHD & large holder of AUXL, ALTH)
- Orbimed Advisors -- (Added to positions in ALTH & BMRN)
- Third Point -- (Activist and large holder of NABI & LGND)

Attributes to look for

- Market to themselves
- Unknown or unloved
- Game changing technology -- Wow! Factor
- Strong insider roster

BOOM & DOOM

PROTECTING & BUILDING YOUR FINANCIAL FUTURE



INVESTOR'S DAILY EDGE



MT. VERNON
RESEARCH

Potential 10 Baggers

Cytori Therapeutics (Nasdaq: CYTX)

BOOM & DOOM

PROTECTING & BUILDING YOUR FINANCIAL FUTURE



INVESTOR'S DAILY EDGE



MT. VERNON
RESEARCH

Cytori's Celution System




Potential 10 Baggers

Cytori Therapeutics (Nasdaq: CYTX)

Medivation (Nadsaq: MDVN)

Significant Volume Loss in AD Patients' Brains



Dimebon at 1 Year well-tolerated vs. marketed AD drugs at only 6 months

Incidence of GI-related adverse events other than dry mouth were <3%, lower than that typically reported with currently marketed cholinesterase inhibitors for AD

	Adverse Events	Incidence
Dimebon	Dry mouth	18%
	All other GI AEs	<3%
Aricept (donepezil)	Nausea	11%
	Vomiting	5%
	Diarrhea	10%
Exelon (rivastigmine)	Nausea	47%
	Vomiting	31%
	Diarrhea	19%
	Anorexia	17%
Razadyne (galantamine)	Nausea	24%
	Vomiting	13%
	Diarrhea	9%
	Anorexia	9%